According to the Shanghai branch of the Chinese Academy of Sciences, said China has independent intellectual property rights of anti-AIDS drug candidate, Nigerian non-Rivero by the State Food and Drug Administration approval to enter clinical trials.
Nepalese non-Rivero can be an effective barrier to HIV prior to the invasion, its anti-infection with the international effects of a similar drug candidates, the drug led by two scientists in Shanghai developed.
It is learnt that the current clinical use of the Kangai Yao, the general role of the virus penetrated the body's cells, making AIDS patients in the advanced reduce deaths and complications arise, to extend their survival time. However, these drugs have significant side effects, and because the use of ineffective alone, to be combined with other Kangai Yao use costly.
At present all scientists began to studyof the goal, to a group called the CCR five chemokine receptors. Nepalese non-Rivero, one of the research and development, the Shanghai Organic Chemistry by the Chinese Academy of Sciences researcher Ma has said, CCR five widespread in the normal human immune cells and help HIV is the key to the invasion of the media. After more than 100 of the screening, they found that a compound can effectively block the 'medium' role, thereby inhibiting the virus into the cell body. Ma has said, Nigeria-Rivero the greatest significance lies in the line of defense after the invasion from HIV, the former moved to the pre-invasion.
When the market for new drugs, Ma has said that generally speaking, the clinical trials of new drugs at least need more than three years, when AIDS patients can be used on the Nigeria-Rivero, depends on the results of clinical trials may be. As for prices, he said, Nigeria-Rivero, the state-owned brand, the listing should be similar than the international drug cheaper.
